

September 20, 2017

IMMUDYNE™

ImmuDyne Forecasts Record Third Quarter 2017 Revenue

MT. KISCO, N.Y., Sept. 20, 2017 (GLOBE NEWSWIRE) -- ImmuDyne, Inc. (OTCQB:IMMD) ("ImmuDyne" or the "Company"), a leader in the development and online marketing of OTC health and wellness products addressing large unmet needs, today announced that it expects record revenue in the third fiscal quarter of 2017.

ImmuDyne, Inc. reported unaudited Gross Revenue of \$623,000 in the month of July and \$738,000 in unaudited Gross Revenue in the month of August. Third quarter unaudited revenue numbers, which will include the month of September, will be released no later than October 15, 2017. The majority of revenue growth in the second quarter came from ImmuDyne's online direct-response marketing business. The Company anticipates continued double digit quarter-over-quarter revenue growth from its new Shapiro MD product line, as well as from 2 new products that will be launched in the fourth quarter of 2017.

"We are extremely pleased with the traction we've seen this quarter, especially with Shapiro MD," stated Mark McLaughlin, CEO of Immudyne. "Although it's great to be able to announce record revenue numbers, we believe this is only the beginning for the Shapiro MD product line and for our online direct-response marketing business."

About Shapiro MD™

The Shapiro MD product line is the result of 15 years of research and development by thought-leading dermatologists Dr. Steven Shapiro and Dr. Michael Borenstein. It is protected by two U.S. patents and is the only product in the hair loss vertical that contains what we believe are the 3 most powerful, naturally-occurring dihydrotestosterone (DHT) blocking ingredients. DHT is widely believed to be the main culprit of balding/hair-loss. For more information on Shapiro MD or to purchase the product, please visit www.shapiromd.com.

About Immudyne

Immudyne, Inc. (the "Company") is a health and wellness company that develops, manufactures, and markets innovative consumer products. Immudyne manufactures and markets a proprietary and patent protected Yeast Beta Glucan that has been shown in thousands of clinical studies to support and regulate the human immune system. It has broad applications in skincare and as an immune support supplement. Immudyne PR, a majority owned subsidiary of ImmuDyne, Inc., is the digital marketing arm of Immudyne and is currently focused on marketing products for thicker and fuller hair (Shapiro MD) and a skincare line containing Immudyne's proprietary Yeast Beta Glucan ingredient (Inate MD). All of Immudyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com

Forward-Looking Statements

Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to ImmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.

The preliminary, unaudited information provided above is based on the Company's current estimate of results from operations for the second quarter and its cash at June 30, 2017, and remains subject to change based on the Company's closing procedures, including the subsequent occurrence or identification of events prior to the formal issuance of the quarterly financial statements.

Contact:

ImmuDyne, Inc.

Bernard Girma +1-949-215-7754

bfgirma@immudyne.com

Source: ImmuDyne, Inc.